Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access, 2) on adaptive clinical trial designs, and 3) on pediatric drug development needs.
The Center for Health Market Innovations (CHMI) has compiled profiles on over 1,200 programs and counting. For TB innovations, the CHMI database contains 58 programs that work on TB in 33 countries.
World TB Day is celebrated on March 24 and there is a lot going on during this week and next to highlight the continued problem of TB in the world and the solutions to address the problem. Included is a list of publications, news items, events, and links related to TB and World TB Day 2013.
The FDA granted Janssen’s TB drug Bedaquiline accelerated approval for treatment of MDR-TB. A link is provided to the FDA press release and Janssen’s full press release is included.
The WHO released the Global Tuberculosis Report 2012 today. The main highlights and additional coverage are included.
This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.
This week we highlight a study showing promising results that providing high dose vitamin D supplements along with antibiotics could improve treatment outcomes for TB patients. The abstract and additional news coverage are included, as well as, links to other TB R&D news.
We will have our 2012 Annual Meeting in Kuala, Lumpur on Wednesday, November 14 at the Impiana KLCC Hotel from 13:00 to 17:30. The meeting will be held in conjunction with the 43rd Union World Conference on Lung Health.
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.
TB REACH is currently accepting applications for Wave 3. The deadline for submitting proposals for Wave 3 is 17 September 2012.